Safety, effectiveness and compliance study of Wepox dispopen 20000 IU in the management of Anemia due to Chronic kidney disease.
Phase 4
- Conditions
- Health Condition 1: D631- Anemia in chronic kidney disease
- Registration Number
- CTRI/2023/10/058943
- Lead Sponsor
- Wockhardt Ltd
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
1. Adult patient (age 18-75 years) of any gender.
2. Patients newly prescribed with WEPOX Dispopen 20000 IU for anemia due to chronic kidney disease (CKD).
3. Patient willing to comply with the protocol and written Informed Consent.
Exclusion Criteria
1.Patients who do not meet requirement as per prescribing information of WEPOX Dispopen 20000 IU
2.Pregnant and lactating females
Study & Design
- Study Type
- PMS
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method